Author/Authors :
Ioannidis، نويسنده , , Panayotis and Kottaridi، نويسنده , , Christine and Dimitriadis، نويسنده , , Euthimios and Courtis، نويسنده , , Nelly and Mahaira، نويسنده , , Louiza and Talieri، نويسنده , , Maroulio and Giannopoulos، نويسنده , , Andreas and Iliadis، نويسنده , , Kosmas and Papaioannou، نويسنده , , Dimitrios and Nasioulas، نويسنده , , George and Trangas، نويسنده , , Theoni، نويسنده ,
Abstract :
The coding region determinant-binding protein (CRD-BP) is an RNA binding protein that recognizes c-myc and IGF-II leader 3 mRNAs as well as the oncofetal H19 RNA. CRD-BP exhibits an oncofetal pattern of expression and has been detected in the majority of colon (81%), breast (58.5%) and sarcoma (73%) tumors. The study of CRD-BP expression was extended in brain tumors and Non small cell lung (NSCL) carcinomas and 12/24 malignant, 2/5 benign neuroepithelial tumors and 4/15 of NSCL carcinomas were found positive. All normal matching tissues tested were found negative. The highest frequency (60%) of CRD-BP positive tumors was observed in meningiomas, either benign (11/18) or atypical (3/3). These findings confirm that CRD-BP expression is restricted in tumors; the frequency of its de novo expression may vary according to tumor type and appears to be an early event in the transformation process.
Keywords :
c-myc mRNA binding protein , Coding region determinant-binding protein , Non small cell lung cancer , Brain tumors
